New imaging agent could light up rare tumors
NCT ID NCT05636540
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing an investigational radioactive tracer called 18F-FluorThanatrace (FTT) for PET/CT scans in up to 30 people with pheochromocytoma or paraganglioma—rare tumors of the adrenal glands or nerve tissue. The tracer aims to measure a protein called PARP-1 in the tumors. Importantly, the scan results will not be used to guide treatment; this is purely an observational study to see if the tracer can effectively highlight these tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-FluorThanatrace ([18F]FTT) - an investigational radioactive tracer for PET/CT imaging
- What this could lead to
- If successful, this could lead to a new imaging method to better see and understand these rare tumors, potentially helping future treatment decisions.
- What could go wrong
- This is a very early, small study (30 people) that is purely observational—it won't change treatment. The tracer may not reliably highlight tumors, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARAGANGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors
- Could a smartphone replace clinic visits for rare tumor survivors?
- Could a cancer drug quiet overactive adrenal hormones? a new study investigates.